Effect of Previous Administration of Potassium Iodine and Different Durations of Low Iodine Diets for Radioiodine Therapy on the Treatment of Graves' Disease in Iodine-rich Areas

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2023 Nov 26

PMID 38008728

Authors

Mika Tamura

Kunihiro Nakada

Haruna Iwanaga

Naotoshi Fujita

Katsuhiko Kato

Affiliations

Soon will be listed here.

Abstract

Purpose: To examine whether adherence to a low-iodine diet (LID) enhances the therapeutic efficacy of radioiodine therapy (RAI) in Graves' hyperthyroidism (GH) in iodine-rich areas.

Methods: We retrospectively evaluated 185 patients with GH from Aichi (n = 114) and Hokkaido (n = 71) Prefectures. Patients aged ≥ 18 years with GH who underwent RAI between December 2012 and March 2022 were divided into subgroups based on pretreatment with anti-thyroid drug (ATD) or potassium iodide (KI). Patients were followed up with LID from 18 days (group A) or 7 days (group H) before RAI to 3 days after RAI. The dose of radioactive iodine 131 (I) was adjusted to deliver > 100 Gy to the thyroid. The associations between urinary iodine concentration on UIC2 vs. 24hRU and UIC2 vs. the 1-year RAI success rate (SR) were investigated.

Results: Compared with UIC1, UIC2 was significantly decreased in all subgroups (P < 0.01). An inverse correlation between UIC2 and 24hRU was observed in the four groups; however, the difference was insignificant. The SR in groups A and H was 85% and 89%, respectively. Univariate analysis revealed no association between UIC2 and SR in each group. Additionally, stratification of the 185 patients into quartiles using UIC2 yielded no significant differences in SR (p = 0.79).

Conclusions: LID sufficiently reduced UIC in patients undergoing RAI. Although a lower UIC2 may increase 24hRU, it did not increase the success of RAI. The benefit of LID in enhancing the efficacy of RAI in GH treatment remains uncertain.

References

Kartamihardja A, Massora S . The Influence of Antithyroid Drug Discontinuation to the Therapeutic Efficacy of (131)I in Hyperthyroidism. World J Nucl Med. 2016; 15(2):81-4. PMC: 4809159. DOI: 10.4103/1450-1147.167584. View

Santarosa V, Orlandi D, Fiorin L, Kasamatsu T, Furuzawa G, Kunii I . Low iodine diet does not improve the efficacy of radioiodine for the treatment of Graves' disease. Arch Endocrinol Metab. 2015; 59(6):501-6. DOI: 10.1590/2359-3997000000082. View

Yoshihara A, Yoshimura Noh J, Watanabe N, Mukasa K, Ohye H, Suzuki M . Substituting Potassium Iodide for Methimazole as the Treatment for Graves' Disease During the First Trimester May Reduce the Incidence of Congenital Anomalies: A Retrospective Study at a Single Medical Institution in Japan. Thyroid. 2015; 25(10):1155-61. DOI: 10.1089/thy.2014.0581. View

Sohn S, Choi J, Jang H, Kim H, Jin S, Kim S . Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer. Thyroid. 2012; 23(6):741-7. PMC: 3675834. DOI: 10.1089/thy.2012.0136. View

Lee M, Lee Y, Jeon T, Chang H, Kim B, Lee Y . Low iodine diet for one week is sufficient for adequate preparation of high dose radioactive iodine ablation therapy of differentiated thyroid cancer patients in iodine-rich areas. Thyroid. 2014; 24(8):1289-96. DOI: 10.1089/thy.2013.0695. View

Erem C, Kandemir N, Hacihasanoglu A, Ersoz H, Ukinc K, Kocak M . Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. Endocrine. 2004; 25(1):55-60. DOI: 10.1385/endo:25:1:55. View

Zava T, Zava D . Assessment of Japanese iodine intake based on seaweed consumption in Japan: A literature-based analysis. Thyroid Res. 2011; 4:14. PMC: 3204293. DOI: 10.1186/1756-6614-4-14. View

Nishio R, Uchida T, Suzuki L, Onose H, Goto H, Yamada E . Influence of Short-Term Dietary and Therapeutic Iodine Restriction on the Therapeutic Effects of Radioactive Iodine Therapy in Patients with Graves' Disease. Thyroid. 2020; 31(3):439-445. DOI: 10.1089/thy.2020.0126. View

Tamura M, Nakada K, Tsuruhara R, Kawamura N, Kawagishi S, Furuta Y . Efficacy of Dietitian-instructed Low Iodine Diet for Radioiodine Remnant Tissue Ablation for Thyroid Cancer. Kaku Igaku. 2017; 53(1):53-60. DOI: 10.18893/kakuigaku.oa.1603. View

10.

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

11.

Andrade V, Gross J, Maia A . The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab. 2001; 86(8):3488-93. DOI: 10.1210/jcem.86.8.7707. View

12.

Ohashi T, Yamaki M, Pandav C, Karmarkar M, Irie M . Simple microplate method for determination of urinary iodine. Clin Chem. 2000; 46(4):529-36. View

13.

Moon J, Yi K . The diagnosis and management of hyperthyroidism in Korea: consensus report of the korean thyroid association. Endocrinol Metab (Seoul). 2014; 28(4):275-9. PMC: 3871036. DOI: 10.3803/EnM.2013.28.4.275. View

14.

Silberstein E, Alavi A, Balon H, Clarke S, Divgi C, Gelfand M . The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012; 53(10):1633-51. DOI: 10.2967/jnumed.112.105148. View

15.

Fuse Y, Ito Y, Shishiba Y, Irie M . Current Iodine Status in Japan: A Cross-sectional Nationwide Survey of Schoolchildren, 2014-2019. J Clin Endocrinol Metab. 2021; 107(5):e2065-e2079. DOI: 10.1210/clinem/dgab919. View

16.

MARINELLI L, QUIMBY E, HINE G . Dosage determination with radioactive isotopes; practical considerations in therapy and protection. Am J Roentgenol Radium Ther. 1948; 59(2):260-81. View

17.

Allahabadia A, Daykin J, Sheppard M, Gough S, Franklyn J . Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab. 2001; 86(8):3611-7. DOI: 10.1210/jcem.86.8.7781. View

18.

Okamura K, Sato K, Fujikawa M, Bandai S, Ikenoue H, Kitazono T . Remission after potassium iodide therapy in patients with Graves' hyperthyroidism exhibiting thionamide-associated side effects. J Clin Endocrinol Metab. 2014; 99(11):3995-4002. DOI: 10.1210/jc.2013-4466. View

19.

Sato S, Yoshimura Noh J, Sato S, Suzuki M, Yasuda S, Matsumoto M . Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism. Thyroid. 2014; 25(1):43-50. DOI: 10.1089/thy.2014.0084. View

20.

Pirnat E, Zaletel K, Gaberscek S, Hojker S . The outcome of 131I treatment in Graves' patients pretreated or not with methimazole. Hell J Nucl Med. 2011; 14(1):25-9. View